Breaking News Bar

Business News and Information

Prelude Therapeutics boosts IPO proceeds target to up to $158M

The company is poised to become the fifth Philadelphia-area life sciences companies to go public this year through an IPO.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear